- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07405177
En studie av MK-7240 hos friska deltagare
En randomiserad, öppen, parallellgruppsstudie för att bedöma den farmakokinetiska bioekvivalensen av subkutant administrerad Tulisokibart som administreras med 2 olika autoinjektorer hos friska deltagare
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Queensland
-
Brisbane, Queensland, Australien, 4006
- Nucleus Network ( Site 0002)
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Nucleus Network ( Site 0001)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
The main inclusion criteria include but are not limited to the following:
- Has a body-mass index (BMI) between 18 and 32 kg/m^2
Exclusion Criteria
The main exclusion criteria include but are not limited to the following:
- Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection
- Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1: Tulisokibart Form 1
Participants will receive tulisokibart form 1. |
Solution for injection.
Andra namn:
|
|
Experimentell: Arm 2: Tulisokibart Form 2
Participants will receive tulisokibart form 2. |
Solution for injection.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the AUC0-inf of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the AUC0-last of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Maximum Plasma Concentration (Cmax) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the Cmax of tulisokibart. |
At designated timepoints up to 14 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants Who Experience an Adverse Event (AE)
Tidsram: At designated timepoints up to 14 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
At designated timepoints up to 14 weeks
|
|
Number of Participants Who Discontinue Study Due to an AE
Tidsram: At designated timepoints up to 14 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
At designated timepoints up to 14 weeks
|
|
Time to Maximum Plasma Concentration (Tmax) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the Tmax of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Apparent Clearance (CL/F) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the CL/F of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Apparent Volume of Distribution (V/F) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the V/F of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Apparent Terminal Half-life (t1/2) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the t1/2 of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Apparent Terminal Elimination Rate constant (Kel) of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the Kel of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Ratio of AUC0-Last/AUC0-Inf of Tulisokibart
Tidsram: At designated timepoints up to 14 weeks
|
Blood samples will be collected to determine the ratio of AUC0-last/AUC0-inf of tulisokibart. |
At designated timepoints up to 14 weeks
|
|
Area Under the Concentration-Time Curve from Time 0 to Day 14 (pAUC0-14) of Tulisokibart
Tidsram: At designated timepoints up to 14 days
|
Blood samples will be collected to determine pAUC0-14 of tulisokibart. |
At designated timepoints up to 14 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Medical Director, Merck Sharp & Dohme LLC
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 7240-009
- MK-7240-009 (Annan identifierare: MSD)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .